| Literature DB >> 24364860 |
Roberto Mempin, Helen Tran, Connie Chen, Hao Gong, Katharina Kim Ho, Sangwei Lu1.
Abstract
BACKGROUND: Adenosine triphosphate (ATP) is used as an intracellular energy source by all living organisms. It plays a central role in the respiration and metabolism, and is the most important energy supplier in many enzymatic reactions. Its critical role as the energy storage molecule makes it extremely valuable to all cells.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24364860 PMCID: PMC3882102 DOI: 10.1186/1471-2180-13-301
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Bacterial strains used
| | | | |
| | MG1655 | Dr. Sydney Kustu, UC Berkeley | |
| | BW25113 | Coli Genetic Stock Center, Yale University | |
| | KSU-9 | Animal isolate of | [ |
| | KSU-12 | Animal isolate of | [ |
| | |||
| | SE2472 | Clinical isolate, Phage type 4 | [ |
| | SE6782 | Clinical isolate, Phage type 4 | [ |
| | SE8464 | Clinical isolate, Phage type 4 | [ |
| | SE8743 | Clinical isolate, Phage type 4 | [ |
| | SE10871 | Clinical isolate, Phage type 4 | [ |
| | SE4052 | Clinical isolate, Phage type 8 | [ |
| | SE4081 | Clinical isolate, Phage type 8 | [ |
| | SE4191 | Clinical isolate, Phage type 8 | [ |
| | SE4241 | Clinical isolate, Phage type 8 | [ |
| | SE4386 | Clinical isolate, Phage type 8 | [ |
| | SE2107 | Clinical isolate, Phage type unknown | [ |
| | SE2606 | Clinical isolate, Phage type 8 | [ |
| | SE0052 | Clinical isolate, Phage type 13 | [ |
| | SE0718 | Clinical isolate, Phage type 4 | [ |
| | SE0430 | Clinical isolate, Phage type 4 | [ |
| | |||
| | ST3665 | Clinical isolate | [ |
| | ST3744 | Clinical isolate | [ |
| | ST3964 | Clinical isolate | [ |
| | ST3864 | Clinical isolate | [ |
| | ST10428 | Clinical isolate | [ |
| | ST2258 | Clinical isolate | [ |
| | ST2297 | Clinical isolate | [ |
| | ST2298 | Clinical isolate | [ |
| | ST2302 | Clinical isolate | [ |
| | ST2327 | Clinical isolate | [ |
| | | ||
| | AJ4970 | Clinical isolate | This study |
| | AJ4978 | Clinical isolate | This study |
| | | ||
| | PA292 | Clinical isolate, CDPH* | This study |
| | PA4553 | Clinical isolate, CDPH* | This study |
| | | ||
| | KP2320 | Clinical isolate, CDPH* | This study |
| | KP7690 | Clinical isolate, CDPH* | This study |
| | | ||
| | KO76 | Clinical isolate, CDPH* | This study |
| | | ||
| | SA25923 | Clinical isolate | ATCC |
| MRSA43300 | Clinical isolate | ATCC | |
* CDPH, California Department of Public Health.
and mutant strains
| Δ | SE2472 Δ | This study |
| Δ | SE2472 Δ | This study |
| Δ | SE2472 Δ | This study |
| | | |
| BW25113 (wild type) | CGSC#: 7636 | [ |
| JW0960-1 | [ | |
| JW0723-2 | [ | |
| JW0422-1 | [ | |
| JW0420-1 | [ | |
| JW0419-1 | [ |
Oligo nucleotides used for mutagenesis
| cyoA5KO | Mutagenesis of | 5′-ctcaggaaatacaataaaagtttgggatggttgtcattaattgcaggcactgcattactcagtggct gtaattctgcgctgctggatcccgtgtaggctggagctgcttc-3′ |
| cyoA3KO | Mutagenesis of | 5′-caacccttggagttggcggattccgcgtggctcatgtccataccttccattccttcatgcgagctgtgc tcaccttcaggttgggtcatgcatatgaatatcctccttag-3′ |
| cyoB5KO | Mutagenesis of | 5′-ataataagcaatcgttgcctgcgattaccctcgcagctattggggttgtctacggtgatattggt accagcccgctttatacgcttcgtgaatgtttgtcgtgtaggctggagctgcttc-3′ |
| cyoB3KO | Mutagenesis of | 5′-aaattatcactggatgcagtaccgttccatgaacctatcgtcatggtaacgatcgctgcaattatcgtc gggggactggcgatactggcagtgtaggctggagctgcttc -3′ |
| cyoC5KO | Mutagenesis of | 5′-tgcattctgttctctattctgtttgctacctatgccgttctggtgaacggcaccgctggcggcccgacaggt aaggacattttcgaactggtgtaggctggagctgcttc -3′ |
| cyoD3KO | Mutagenesis of | 5′-tgtagttgaggttccacataatccagatggagcccacaaccaggatggcgatgatcagcacggtaaag atgaaggccgtcatgttccagcatatgaatatcctccttag -3′ |
| cyoA5 | Confirmation of | 5′-atcatgtttacagtaatgta-3′ |
| cyoA3 | Confirmation of | 5′-tccgaacatcttatcttcct -3′ |
| cyoB5 | Confirmation of | 5′-aggaagataagatgttcgga-3′ |
| cyoB3 | Confirmation of | 5′-tcgcgtgcgttaaagtatca -3′ |
| cyoCD5 | Confirmation of | 5′-tgatactttaacgcacgcga -3′ |
| cyoCD3 | Confirmation of | 5′-tgcaggtattgcttaaacat-3′ |
| K1 | KanR primer for confirmation of mutation | 5′-cagtcatagccgaatagcct-3′ |
| K2 | KanR primer for confirmation of mutation | 5′-cggtgccctgaatgaactgca-3′ |
Figure 1ATP is present in the bacterial culture supernatant and the extracellular ATP is not due to bacteria contamination. Overnight culture of Salmonella strain SE2472 was diluted 1:100 in LB and cultured at 37°C for 3 hours with shaking to reach early log phase. The overnight (stationary) and 3 hour (early log phase) cultures were spun down. An aliquot of each culture supernatant was filtered through a 0.22 μm filter to remove any residual bacteria. ATP levels in the filtered (hatched bars) or unfiltered culture supernatant (open bars) were measured. Results are the average of 3 assays and error bars represent standard deviations.
Figure 2ATP is present in the culture media of clinical and laboratory strains of and during growth. Overnight culture of each isolate was diluted 1:100 in fresh LB and cultured at 37°C with shaking. Early log phase bacterial cultures were harvested at 3 hours of incubation and ATP assays were carried out with culture supernatant. The ATP concentration was plotted for each bacterial isolate of E. coli, Salmonella enterica Serovar Enteritidis (SE) or Salmonella enterica Serovar Typhimurium (ST). The experiment was performed three times and results are from a representative experiment.
Figure 3Extracellular ATP level changes during bacteria growth. Overnight cultures of Salmonella SE2472 (A) or ST14028s (B), E. coli K12 (C) or BW25113 (D), were diluted 1:100 in LB broth and cultured at 37°C with shaking. Aliquots were collected at various time points for measuring OD600nm and culture supernatant was harvested for ATP assays. The ATP levels in the culture supernatant were normalized against OD600nm and plotted against incubation period. Results are the average from 3 to 8 experiments and error bars represent standard deviations.
Peak ATP levels in culture supernatant of terminal oxidase mutants of
| Cytochrome bd-I oxidase | Defective | 1.3 ± 2.2 | < 0.05 | |
| Cytochrome bd-II oxidase | Normal | 95.0 ± 2.5 | < 0.05 | |
| Cytochrome bo oxidase | Normal | 25.0 ± 3.7 | < 0.05 | |
| | Normal | 36.6 ± 1.5 | < 0.05 | |
| Normal | 26.1 ± 5.4 | < 0.05 |
Results are the average of three assays with standard deviations.
Figure 4The mutants of BW25113 and SE2472 have lower extracellular ATP levels during growth. Overnight cultures of wild type (WT) or ∆cyo mutants of E. coli(A and B) or Salmonella(C and D) were diluted 1:100 in fresh LB broth and cultured at 37°C with shaking. Aliquots were collected at various time points and ATP assays were carried out with culture supernatant or whole culture. The ATP levels in the culture supernatant (A and C) or whole culture (B and D) were normalized using OD600nm and plotted against the incubation period. Results are the average of 3 experiments and error bars represent standard deviations.
Figure 5Live bacteria deplete ATP in the culture medium. (A) and (B) Live or heat – killed E. coli K12 (A) or Salmonella SE2472 (B) were spun down and incubated at 37°C in fresh LB supplemented with 10 μM ATP. Culture supernatant from live bacteria was supplemented with ATP to 10 μM. ATP depletion by bacteria cells or culture supernatant was measured by the residual ATP level in culture medium after various culture periods of incubation at 37°C. The residual ATP levels were plotted against the incubation period. (C) and (D) Free and cell-associated ATP in E. coli(C) or Salmonella(D) culture incubated with S35-α-ATP or P32-γ-ATP. The relative levels of radioactivity in culture supernatant and bacterial cells were determined and plotted against the incubation period. Each experiment was performed three times and results are from a representative experiment.
Figure 6ATP supplementation increases the stationary survival of bacteria.E. coli K12, Salmonella enterica Serovar Enteritidis (SE) or Salmonella enterica Serovar Typhimurium (ST) was cultured in M9 minimal medium or M9 minimal medium supplemented with 10 μM or 100 μM of ATP. The rate of survival was determined by comparing bacterial CFU/mL after 7 days of incubation to that after 1 day of incubation. The experiment was performed three times and results are from a representative experiment performed in triplicate. Error bars represent standard deviation. * p < 0.05, Student’s t-test.
Extracellular ATP from various bacterial species
| AJ4970 | 6 | 255.2 ± 56.8 | |
| AJ4978 | 6 | 17.0 ± 1.1 | |
| PA292 | 6 | 25.5 ± 1.1 | |
| PA4553 | 3 | 20.5 ± 0.6 | |
| KP7690 | 9 | 9.3 ± 0.5 | |
| KP2320 | 9 | 1.0 ± 0.0 | |
| KO76 | 3 | 31.1 ± 4.0 | |
| SA25923 | 6 | 21.4 ± 3.5 | |
| MRSA43300 | 6 | 19.3 ± 1.3 |
Results are the average of three assays with standard deviations.
Figure 7ATP levels in the cultures of . Overnight cultures of two clinical isolates of Acinetobacter junii AJ4970 and AJ4978 were diluted 1:100 in fresh LB broth and cultured at 37°C with shaking. Aliquots were collected at various time points and ATP levels in the culture supernatant and the bacterial pellet were determined. (A) ATP levels in the culture supernatant. ATP concentrations were determined and plotted against the incubation period. (B) ATP levels in the bacterial pellet. Total ATP levels in the bacterial pellet were normalized against OD600nm of each culture and plotted against the incubation time period. (C) Ratio of quantity of ATP in the culture supernatant to that of the bacterial cells. Acinetobacter junii cultures were spun down and separated into culture supernatant and cell pellet. ATP levels in each fraction were determined. The ratio of ATP from supernatant to that of bacterial cells from the same volumes of cultures was plotted against the incubation period. Results are the average of 4 experiments and error bars represent standard deviations.